Neuropathic Pain in Psoriatic Arthritis

Status Completed

Clinical Trial Summary

Pathogenesis of inflammatory diseases is suitable for eliciting neuropathic pain. The aim of this study is to evaluate the frequency of NP among PsA patients and relationship between disease activity, quality of life, functionality, and other numerous factors.

Clinical Trial Description

Neuropathic pain (NP) is the pain arising from a primary lesion or a dysfunction of nervous system. NP can affect central or peripheral nervous system and can be caused by numerous factors such as inflammation or neuroplastic changes. Inflammation can sensitize nociceptors in sensory nerves by promoting prostaglandin E2 and I2 secretion thus, cause neuropathic pain. Besides, a mixed pain pattern with neuropathic components is thought to be developed in chronic pain conditions. In this point of view, pathogenesis of inflammatory diseases is suitable for eliciting NP. In arthritic joints, even non-arthritic tissues are affected by the disease and a condition called peripheral sensitization develops. Previous studies about NP and inflammatory diseases link have focused on rheumatoid arthritis and number of studies about NP and psoriatic arthritis (PsA) is limited. In this manner the aim of this study is to evaluate the frequency of NP among PsA patients and relationship between disease activity, quality of life, functionality, and other numerous factors. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05223049
Study type	Observational
Source	Bezmialem Vakif University
Contact
Status	Completed
Phase
Start date	January 22, 2022
Completion date	March 15, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04152759` - Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects	Phase 1
Completed	`NCT03248518` - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases	N/A
Completed	`NCT01925768` - Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis	Phase 3
Completed	`NCT01892436` - Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis	Phase 3
Completed	`NCT01212770` - PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis	Phase 3
Completed	`NCT05051943` - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed	`NCT01212757` - PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis	Phase 3
Completed	`NCT03953378` - CD73+ Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis
Recruiting	`NCT02572700` - Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis
Completed	`NCT02556034` - Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA.
Completed	`NCT02154425` - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers	Phase 1
Completed	`NCT02188654` - Metformin in Psoriatic Arthritis	N/A
Completed	`NCT02164214` - Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)?	Phase 3
Completed	`NCT01392326` - Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)	Phase 3
Completed	`NCT01083693` - Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs	N/A
Not yet recruiting	`NCT00517101` - Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy	N/A
Completed	`NCT00133315` - TNFalfa Blocking Treatment of Spondylarthropathies	Phase 4
Completed	`NCT00659412` - A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis	Phase 2
Completed	`NCT00946686` - To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions	Phase 1
Not yet recruiting	`NCT06059430` - Cohort Project of Patients With Inflammatory Rheumatism